Iron Sodium Citrate

Iron sodium citrate delivers ferrous iron (Fe²⁺) complexed with citrate that is absorbed via the duodenal divalent metal transporter 1 (DMT1), exploiting the superior intestinal uptake of the reduced ferrous state over ferric formulations. In a phase 3 non-inferiority trial of 180 iron-deficiency anemia patients, sodium ferrous citrate at 100 mg/day achieved target hemoglobin (≥12 g/dL) in 68% of women versus 62% for ferric citrate hydrate, while producing significantly less nausea (4% vs. 12%) and vomiting (2% vs. 8%).

Origin & History

Iron sodium citrate is a synthetically manufactured pharmaceutical compound, not derived from a natural botanical source. It is produced through chemical complexation of ferrous iron (Fe²⁺) with citric acid and sodium, yielding a stable, water-soluble coordination compound with the molecular formula C₁₂H₁₀FeNa₄O₁₄. The compound was developed as a modern clinical formulation to optimize oral iron bioavailability and gastrointestinal tolerability, and is currently approved and manufactured in Japan under the trade name Ferromia® by Eisai Co.

Historical & Cultural Context

Iron sodium citrate is an entirely modern pharmaceutical compound with no documented history in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or Western herbalism. The compound was developed in the latter 20th and early 21st centuries as part of systematic efforts in pharmaceutical chemistry to improve upon the gastrointestinal side-effect profile and bioavailability limitations of earlier iron salts such as ferrous sulfate and ferric ammonium citrate. Its clinical development and regulatory approval occurred in Japan, where Eisai Co. brought Ferromia® to market, reflecting Japan's robust regulatory pathway for novel iron formulations in anemia and nephrology indications. There is no folk, ethnobotanical, or pre-modern cultural record associated with this compound, distinguishing it categorically from plant-derived or mineral-earth iron sources historically used in medicinal traditions.

Health Benefits

- **Iron Deficiency Anemia Correction**: Ferrous iron from iron sodium citrate is absorbed via DMT1 in the duodenum, efficiently replenishing hemoglobin; a phase 3 trial demonstrated target hemoglobin achievement in 68% of female IDA patients at 100 mg/day.
- **Superior Gastrointestinal Tolerability**: The ferrous citrate complex exhibits markedly lower rates of nausea (4%) and vomiting (2%) compared to ferric citrate hydrate (12% and 8%, respectively), improving patient adherence to iron therapy.
- **Serum Iron and Ferritin Restoration**: In iron-deficient hemodialysis patients, 3 months of supplementation raised mean serum iron from 37.4 to 94.6 µg/dL and ferritin from 37.6 to 87.0 ng/mL, demonstrating robust repletion of both circulating and stored iron pools.
- **FGF23 Modulation in Chronic Kidney Disease**: Supplementation significantly reduced intact FGF23 from 1,820 to 1,240 pg/mL and C-terminal FGF23 from 309 to 259 pg/mL in hemodialysis patients, with reductions correlating directly with increases in ferritin, suggesting iron status drives FGF23 dysregulation.
- **Reduction of Systemic Inflammation**: C-reactive protein levels decreased significantly (P < 0.01) in iron-deficient hemodialysis patients receiving oral iron sodium citrate for 3 months, indicating secondary anti-inflammatory effects mediated through improved iron homeostasis.
- **Transferrin Saturation Improvement**: Treatment improved transferrin saturation (TSAT) to a mean of 38.8% in hemodialysis patients, restoring adequate iron transport capacity and reducing functional iron deficiency in a renally compromised population.
- **Neutral Effect on Mineral Metabolism**: Unlike some phosphate-binding iron formulations, iron sodium citrate does not significantly alter serum phosphate, calcium, or intact parathyroid hormone levels, preserving bone and mineral metabolism integrity during supplementation.

How It Works

Iron sodium citrate delivers ferrous iron (Fe²⁺) to the intestinal brush border, where it is transported across the duodenal enterocyte apical membrane via divalent metal transporter 1 (DMT1), the primary high-affinity intestinal iron importer; the ferrous oxidation state is critical because DMT1 transports only Fe²⁺, and the citrate ligand stabilizes this reduced form during gastric transit. Once absorbed, iron enters the body's labile iron pool, replenishing transferrin-bound serum iron and hepatic ferritin stores, which in turn modulates the hepatic hormone hepcidin—the master regulator of systemic iron homeostasis—and downstream iron export via ferroportin on enterocytes and macrophages. In chronic kidney disease, improved iron stores appear to suppress erythropoietic and hypoxic signaling in osteocytes and bone marrow, leading to reduced transcription and secretion of FGF23, a phosphaturic hormone whose elevation is independently associated with cardiovascular mortality in hemodialysis patients. Ascorbic acid co-administration further enhances bioavailability by chemically reducing any Fe³⁺ back to Fe²⁺ in the intestinal lumen, maintaining substrate compatibility with DMT1 and increasing net absorption efficiency.

Scientific Research

The clinical evidence base for iron sodium citrate is small but of reasonable methodological quality within its studied indications, consisting primarily of one phase 3 non-inferiority randomized controlled trial (n=180 IDA patients) and one prospective observational study (n=31 iron-deficient hemodialysis patients), both conducted in Japan. The phase 3 RCT provides the strongest evidence, demonstrating non-inferiority and statistical superiority trends for hemoglobin response and gastrointestinal tolerability versus an active comparator (ferric citrate hydrate), with a comparative serum iron advantage of approximately 15% at 7 weeks. The hemodialysis study, while prospective, lacks a randomized control arm and is underpowered (n=31), and the authors explicitly call for larger RCTs to confirm FGF23 and inflammatory findings. Evidence is currently limited to Japanese clinical populations, with no large multinational trials, meta-analyses, or systematic reviews published on this specific formulation, warranting caution in broad generalization.

Clinical Summary

The pivotal phase 3 non-inferiority trial enrolled 180 iron-deficiency anemia patients randomized to sodium ferrous citrate 100 mg/day or ferric citrate hydrate 500–1,000 mg/day, with the primary endpoint of hemoglobin target achievement (≥12 g/dL for women); sodium ferrous citrate met non-inferiority criteria and numerically outperformed on both efficacy (68% vs. 62%) and gastrointestinal adverse events. A separate 3-month prospective study in 31 iron-deficient maintenance hemodialysis patients demonstrated statistically significant improvements in serum iron (P < 0.0001), ferritin (P < 0.01), FGF23 (P < 0.05), and CRP (P < 0.01), with no adverse impact on phosphate, calcium, or parathyroid hormone. Effect sizes were clinically meaningful—serum iron more than doubled and intact FGF23 declined by approximately 32%—but the small sample size and absence of a concurrent control group limit causal inference for the CKD population. Overall confidence in the IDA indication is moderate-to-good based on RCT data; confidence in the CKD/FGF23 indication remains preliminary pending larger controlled trials.

Nutritional Profile

Iron sodium citrate contributes elemental iron as its primary nutritional constituent, delivered in the bioavailable ferrous (Fe²⁺) form; a 50 mg tablet provides a defined quantity of elemental iron calibrated to the molecular weight of the complex (C₁₂H₁₀FeNa₄O₁₄, MW ≈ 543.96 g/mol), yielding approximately 10.3% elemental iron by mass. The compound also delivers sodium and citrate as co-ligands; citrate is a tricarboxylic acid cycle intermediate that may offer minor alkalinizing effects but contributes negligible caloric or macronutrient value at supplemental doses. Bioavailability is enhanced relative to ferric formulations due to the pre-reduced Fe²⁺ state and the chelating effect of citrate, which maintains iron solubility across a range of intestinal pH environments; absorption efficiency is further modulated by body iron stores (regulated by hepcidin), concurrent dietary tannins, phytates, calcium, and antacids, which can inhibit uptake.

Preparation & Dosage

- **Oral Tablet (Japan, Ferromia®)**: 50 mg tablets; standard clinical trial dose is 100 mg/day (two tablets), taken orally for iron deficiency anemia treatment.
- **Liquid/Soluble Forms**: The compound's high water solubility makes it suitable for liquid formulation; specific commercial liquid preparations are not yet widely catalogued outside Japan.
- **Iron Deficiency Anemia (Clinical Dose)**: 100 mg elemental iron equivalent per day, as studied in phase 3 RCT; duration typically continued until hemoglobin target (≥12 g/dL women, ≥13 g/dL men) is achieved and iron stores are replete.
- **Hemodialysis/CKD Population**: Oral supplementation at low-dose regimens (study employed standard 100 mg/day equivalent) for a minimum of 3 months to achieve measurable improvements in ferritin and FGF23 modulation.
- **Timing**: Oral iron is generally best absorbed on an empty stomach or 30–60 minutes before meals; co-administration with ascorbic acid (vitamin C, 200–500 mg) is recommended to maintain the ferrous state and maximize DMT1-mediated absorption.
- **Standardization**: Compound is defined by molecular formula C₁₂H₁₀FeNa₄O₁₄; pharmaceutical-grade preparations are standardized to defined iron content per tablet (50 mg tablet formulation confirmed in Japanese approval).

Synergy & Pairings

Co-administration of ascorbic acid (vitamin C, 200–500 mg) is the most evidence-supported synergistic pairing, as ascorbate maintains ferrous iron (Fe²⁺) in its reduced state within the intestinal lumen, directly preserving substrate compatibility with DMT1 and measurably increasing net iron absorption. Avoiding concurrent consumption of calcium-rich foods, tannin-containing beverages (tea, coffee), and phytate-rich foods (whole grains, legumes) during dosing reduces competitive inhibition at the DMT1 transporter and in the intestinal lumen, functionally amplifying the inherent solubility advantage of the citrate complex. In clinical practice, iron sodium citrate is sometimes combined with erythropoiesis-stimulating agents (ESAs) in the CKD hemodialysis setting, where adequate iron stores are prerequisite for ESA efficacy; this combination addresses the dual deficiency of iron substrate and erythropoietin signaling required for red blood cell production.

Safety & Interactions

At the clinically studied dose of 100 mg/day, iron sodium citrate demonstrates a favorable safety profile with nausea occurring in approximately 4% and vomiting in 2% of IDA patients; these rates are significantly lower than comparator ferric iron formulations and represent its primary tolerability advantage. Iron supplementation as a class carries risk of iron overload (hemosiderosis) in patients with hereditary hemochromatosis, hemolytic anemias, or those receiving concurrent parenteral iron, and supplementation should be guided by serum ferritin and transferrin saturation monitoring. Drug interactions relevant to oral iron include reduced absorption of fluoroquinolone and tetracycline antibiotics, levothyroxine, bisphosphonates, levodopa, and methyldopa when co-administered; a minimum 2-hour separation is standard practice. Pregnancy and lactation use should follow prescribing physician guidance, as iron requirements are elevated in pregnancy but excess iron supplementation carries theoretical oxidative risks; specific safety data for iron sodium citrate in pregnant populations have not been reported in the available literature.